Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase

Pharmacogenomics

Volumn 12, Issue 1, 2011, Pages 49-58

  Georgitsi, Marianthi ^a   Viennas, Emmanouil ^b   Gkantouna, Vassiliki ^b   Christodoulopoulou, Elena ^a   Zagoriti, Zoi ^a   Tafrali, Christina ^a   Ntellos, Fotios ^a   Giannakopoulou, Olga ^a   Boulakou, Athanassia ^a   Vlahopoulou, Panagiota ^a   Kyriacou, Eva ^a   Tsaknakis, John ^b   Tsakalidis, Athanassios ^b   Poulas, Konstantinos ^a   Tzimas, Giannis ^b   Patrinos, George P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

allelic frequencies; data visualization; databases; ethnic groups; markers; pharmacogenomics; populations; SNPs; web

Indexed keywords

ARTICLE; COMPUTER INTERFACE; COMPUTER PROGRAM; DATA MINING; DOCUMENTATION; ETHNIC GROUP; GENE FREQUENCY; GENETIC DATABASE; GENETIC MARKER; HUMAN; PHARMACOGENOMICS; POPULATION GENETICS; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM;

DATABASES, GENETIC; ETHNIC GROUPS; GENE FREQUENCY; GENETIC DISEASES, INBORN; GENETIC MARKERS; GENETICS, POPULATION; HUMANS; PHARMACOGENETICS; USER-COMPUTER INTERFACE;

EID: 78650427535     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.169     Document Type: Article

References (28)

1. Patrinos GP, Innocenti F: Pharmacogenomics: paving the path to personalized medicine. Pharmacogenomics 11(2), 141-146 (2010).
2. Squassina A, Manchia M, Manolopoulos VG et al.: Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11(8), 1149-1167 (2010).
3. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004).
4. Burchard EG, Ziv E, Coyle N et al.: The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348(12), 1170-1175 (2003).
5. Lagoumintzis G, Poulas K, Patrinos GP: Genetic databases and their potential in pharmacogenomics. Curr. Pharm. Des. 16(20), 2224-2231 (2010).
6. Klein TE, Chang JT, Cho MK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics research network and knowledge Base. Pharmacogenomics J. 1(3), 167-170 (2001).
7. Hewett M, Oliver DE, Rubin DL et al.: PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res. 30(1), 163-165 (2002).
8. Van Baal S, Kaimakis P, Phommarinh M et al.: FINDbase: a relational database recording frequencies of genetic defects leading to inherited disorders worldwide. Nucleic Acids Res. 35(Database issue), D690-D695 (2007).
9. Bell M: SOA Modeling Patterns for Service-Oriented Discovery and Analysis. Wiley & Sons, Inc., Hoboken, NJ, USA (2010).
10. Jakubowska A, Gronwald J, Menkiszak J et al.: BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res. Treat. 119(1), 201-211 (2010).
11. Marsh S, Collie-Duguid ES, Li T et al.: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58(3), 310-312 (1999).
12. Lima CS, Ortega MM, Ozelo MC et al.: Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk. Res. 32(3), 401-405 (2008).
13. Man M, Farmen M, Dumaual C et al.: Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharmacol. 50(8), 929-940 (2010).
14. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
15. Ho RH, Choi L, Lee W et al.: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 17(8), 647-656 (2007).
16. Mehlotra RK, Bockarie MJ, Zimmerman PA: Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur. J. Clin. Pharmacol. 63(1), 1-8 (2007).
17. Bolufer P, Collado M, Barragan E et al.: The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica 92(3), 308-314 (2007).
18. Largillier R, Etienne-Grimaldi MC, Formento JL et al.: Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res. 12(18), 5496-5502 (2006).
19. Provenzani A, Notarbartolo M, Labbozzetta M et al.: The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann. Transplant. 14(1), 23-31 (2009).
20. Sim SC, Ingelman-Sundberg M: The human cytochrome P450 Allele Nomenclature Committee Website: submission criteria, procedures, and objectives. Methods Mol. Biol. 320, 183-191 (2006).
21. Morel A, Boisdron-Celle M, Fey L et al.: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fuorouracil tolerance. Mol. Cancer. Ther. 5(11), 2895-2904 (2006).
22. Yen JL, McLeod HL: Should DPD ana lysis be required prior to prescribing fuoropyrimidines? Eur. J. Cancer 43(6), 1011-1016 (2007).
23. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens- Johnson syndrome. Nature 428(6982), 486 (2004).
24. Patrinos GP, Petricoin EF: A new scientifc journal linked to a genetic database: Towards a novel publication modality. Hum. Genomics Proteomics 1(1), e597478 (2009).
25. Thompson EE, Kuttab-Boulos H, Witonsky D et al.: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6), 1059-1069 (2004).
26. Mitropoulou C, Webb AJ, Mitropoulos K et al.: Locus-specifc database domain and data content ana lysis: evolution and content maturation toward clinical use. Hum. Mutat. 31(10), 1109-1116 (2010).
27. Patrinos GP: General considerations for integrating pharmacogenomics into the mainstream medical practice. Hum. Genomics 4(6), 371-374 (2010).
28. Patrinos GP: National and ethnic mutation databases: recording populations' genography. Hum. Mutat. 27(9), 879-887 (2006).